Butyrophilin

How Unique Immune Cells Can Recognize--and Destroy--Tumors

Retrieved on: 
Wednesday, August 30, 2023
San Francisco, CRISPR, University, Nature, Biochemistry, Murad, Hematology, University Medical Center, Neoplasm, Marson, University of California, San Francisco, Cancer, Mamedov, Cell, Doctor of Philosophy, Thought, University Medical Center Utrecht, Gamma delta T cell, UC, MD, Patient, Physician, SAN, Immune system, Butyrophilin, Biology, Bacteria, Gladstone Institutes, Virus, Gene, Genome, Vaccine, Medical imaging, William Ewart Gladstone

SAN FRANCISCO, Aug. 30, 2023 /PRNewswire/ -- Gamma delta T cells, a special type of cell in the immune system, are incredibly effective at recognizing and killing cancer cells. Cancer patients with higher levels of these T cells in their tumors tend to fare better than those with lower levels. But scientists have struggled to understand exactly how gamma delta T cells can recognize cancerous cells, and how new cancer therapies may be able to take advantage of these powerful immune cells.

Key Points: 
  • New study explains how understudied cells in the immune system, called gamma delta T cells, can target cancer cells for destruction
    SAN FRANCISCO, Aug. 30, 2023 /PRNewswire/ -- Gamma delta T cells, a special type of cell in the immune system, are incredibly effective at recognizing and killing cancer cells.
  • But scientists have struggled to understand exactly how gamma delta T cells can recognize cancerous cells, and how new cancer therapies may be able to take advantage of these powerful immune cells.
  • Now, researchers at Gladstone Institutes and UC San Francisco have pinpointed conditions that enable gamma delta T cells to identify cancer cells.
  • "In healthy cells, butyrophilin is invisible to gamma delta T cells, so that T cells don't start killing them," explains Mamedov.

ImCheck Appoints Thomas Civik as Independent Chairman of the Board

Retrieved on: 
Thursday, March 23, 2023
Amgen, Therapy, MBA, Kellogg School, Genentech, Acquisition, Patient, Neurological reparative therapy, Foundation Medicine, FDA, Northwestern University, Management, Pharmaceutical industry, Butyrophilin, Sanofi

Marseille, France, March 23, 2023 – ImCheck Therapeutics announced today the appointment of Thomas Civik as independent Chairman of its Board of Directors.

Key Points: 
  • Marseille, France, March 23, 2023 – ImCheck Therapeutics announced today the appointment of Thomas Civik as independent Chairman of its Board of Directors.
  • He will join ImCheck’s Board as the company further develops its lead program ICT01 and a range of antibody therapeutics targeting butyrophilins, a novel super-family of immunomodulators.
  • Dr. Debasish Roychowdhury, Chairman since 2018, will step down from the Board and remain an advisor to the company.
  • He holds an MBA from the Kellogg School of Management at Northwestern University and currently serves on the Board of Directors at Repare Therapeutics and Pyxis Oncology.

ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Vγ9Vδ2 T Cells in Science Translational Medicine

Retrieved on: 
Wednesday, October 20, 2021
Olive, Lung, Pancreatic cancer, Head, Group C, Cancer, Melanoma, Research, Interferon gamma, Tumor necrosis factor, Prostate, Neoplasm, T, CD8, BTN, Infection, Patient, Science Translational Medicine, IC, Part, Large-cell lung carcinoma, Breast, Antibody, INSERM, Aix-Marseille University, Oncology, Hematological Cancer Research Investment and Education Act, Leadership, Degenerative disease, Malignancy, Doctor of Pharmacy, CD3, Clinical trial, Immunology, NK, Acute myeloid leukemia, Butyrophilin, Follicular lymphoma, Therapy, CNRS, Group B, Acute leukemia, SITC, Pembrolizumab, AACR, Immunomodulation, Ovary, Vaccine, Management

The publication in the medical journal Science Translational Medicine details ImChecks butyrophilin (BTN)-based immuno-oncology approach and positions ImCheck as a pioneer in a nascent field of immunomodulation.

Key Points: 
  • The publication in the medical journal Science Translational Medicine details ImChecks butyrophilin (BTN)-based immuno-oncology approach and positions ImCheck as a pioneer in a nascent field of immunomodulation.
  • In the first-in-human EVICTION Phase I/IIa clinical trial, ICT01 demonstrated selective activation of V9V2 T cells, causing them to rapidly migrate out of the circulation and into tumor tissue.
  • Furthermore, ICT01-activated V9V2 T cells secrete IFN and TNFa that expands the anti-tumor immune response by recruiting CD3 and CD8 T cells into tumors.
  • BTN3A is essential for the activation of the anti-tumor immune response of V9V2 T cells.